|
1
|
Morris CD, Teot LA, Bernstein ML, Marina
N, Krailo MD, Villaluna D, Janeway KA, DuBois SG, Gorlick RG and
Randall RL: Assessment of extent of surgical resection of primary
high-grade osteosarcoma by treating institutions: A report from the
children's oncology group. J Surg Oncol. 113:351–354. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nataraj V, Batra A, Rastogi S, Khan SA,
Sharma MC, Vishnubhatla S and Bakhshi S: Developing a prognostic
model for patients with localized osteosarcoma treated with uniform
chemotherapy protocol without high dose methotrexate: A
single-center experience of 237 patients. J Surg Oncol.
112:662–668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xie L, Liao Y, Shen L, Hu F, Yu S, Zhou Y,
Zhang Y, Yang Y, Li D, Ren M, et al: Identification of the
miRNA-mRNA regulatory network of small cell osteosarcoma based on
RNA-seq. Oncotarget. 8:42525–42536. 2017.PubMed/NCBI
|
|
4
|
Fujiwara T, Uotani K, Yoshida A, Morita T,
Nezu Y, Kobayashi E, Yoshida A, Uehara T, Omori T, Sugiu K, et al:
Clinical significance of circulating miR-25-3p as a novel
diagnostic and prognostic biomarker in osteosarcoma. Oncotarget.
8:33375–33392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gai P, Sun H, Wang G, Xu Q, Qi X, Zhang Z
and Jiang L: miR-22 promotes apoptosis of osteosarcoma cells via
inducing cell cycle arrest. Oncol Lett. 13:2354–2358. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang C, Long F, Wan J, Hu Y and He H:
MicroRNA-205 acts as a tumor suppressor in osteosarcoma via
targeting RUNX2. Oncol Rep. 35:3275–3284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu M, Jin H, Xu CX, Sun B, Mao Z, Bi WZ
and Wang Y: miR-382 inhibits tumor growth and enhance
chemosensitivity in osteosarcoma. Oncotarget. 5:9472–9483. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dai N, Qing Y, Cun Y, Zhong Z, Li C, Zhang
S, Shan J, Yang X, Dai X, Cheng Y, et al: miR-513a-5p regulates
radiosensitivity of osteosarcoma by targeting human
apurinic/apyrimidinic endonuclease. Oncotarget. 9:25414–25426.
2016.PubMed/NCBI
|
|
9
|
He S, Xiao Z, Chen L and Xiong S: Comment
on Xu XW et al: Prognostic significance of VEGF expression
in osteosarcoma: A meta-analysis. Tumour Biol. 35:6193–6194. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohba T, Cates JM, Cole HA, Slosky DA, Haro
H, Ando T, Schwartz HS and Schoenecker JG: Autocrine VEGF/VEGFR1
signaling in a subpopulation of cells associates with aggressive
osteosarcoma. Mol Cancer Res. 12:1100–1111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng J, Chen Y, Zhao P, Liu X, Dong J, Li
J, Huang C, Wu R and Lv Y: Downregulation of miRNA-638 promotes
angiogenesis and growth of hepatocellular carcinoma by targeting
VEGF. Oncotarget. 7:30702–30711. 2016.PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kudawara I, Aoki Y, Ueda T, Araki N, Naka
N, Nakanishi H, Matsumine A, Ieguchi M, Mori S, Myoui A, et al:
Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide,
doxorubicin, cisplatin and high-dose methotrexate in non-metastatic
osteosarcoma of the extremities: A phase II trial in Japan. J
Chemother. 25:41–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao J, Xu H, He M, Wang Z and Wu Y: Rho
GTPase-activating protein 35 rs1052667 polymorphism and
osteosarcoma risk and prognosis. Biomed Res Int. 2014:3969472014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grignani G, Palmerini E, Ferraresi V,
D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y,
Sangiolo D, Marchesi E, et al: Sorafenib and everolimus for
patients with unresectable high-grade osteosarcoma progressing
after standard treatment: A non-randomised phase 2 clinical trial.
Lancet Oncol. 16:98–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin CY, Tzeng HE, Li TM, Chen HT, Lee Y,
Yang YC, Wang SW, Yang WH and Tang CH: WISP-3 inhibition of miR-452
promotes VEGF-A expression in chondrosarcoma cells and induces
endothelial progenitor cells angiogenesis. Oncotarget.
8:39571–39581. 2017.PubMed/NCBI
|
|
17
|
Wang Z, Wen P, Luo X, Fang X, Wang Q, Ma F
and Lv J: Association of the vascular endothelial growth factor
(VEGF) gene single-nucleotide polymorphisms with osteosarcoma
susceptibility in a Chinese population. Tumour Biol. 35:3605–3610.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang C, Zhao Y and Zeng B: Enhanced
chemosensitivity by simultaneously inhibiting cell cycle
progression and promoting apoptosis of drug-resistant osteosarcoma
MG63/DXR cells by targeting Cyclin D1 and Bcl-2. Cancer Biomark.
12:155–167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Zheng Q, Wu H, Guo X, Li J and Hao
S: Rapamycin increases pCREB, Bcl-2, and VEGF-A through ERK under
normoxia. Acta Biochim Biophys Sin (Shanghai). 45:259–267. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Ni J, Yi S, Song D and Ding M:
Protein inhibitor of activated STAT xalpha depresses cyclin D and
cyclin D kinase, and contributes to the inhibition of osteosarcoma
cell progression. Mol Med Rep. 13:1645–1652. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu J, Cui LL, Yuan J, Wang Y and Song S:
Clinical significance of the phosphorylation of MAPK and protein
expression of cyclin D1 in human osteosarcoma tissues. Mol Med Rep.
15:2303–2307. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li P, Liu Y, Yi B, Wang G, You X, Zhao X,
Summer R, Qin Y and Sun J: MicroRNA-638 is highly expressed in
human vascular smooth muscle cells and inhibits PDGF-BB-induced
cell proliferation and migration through targeting orphan nuclear
receptor NOR1. Cardiovasc Res. 99:185–193. 2013. View Article : Google Scholar : PubMed/NCBI
|
